Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'

por Spindler, K-L G, Pallisgaard, N, Andersen, R F, Jakobsen, A
Publicado 2014

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer

por Spindler, K G, Appelt, A L, Pallisgaard, N, Andersen, R F, Jakobsen, A
Publicado 2013

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma

por Thomsen, C. B., Hansen, T. F., Andersen, R. F., Lindebjerg, J., Jensen, L. H., Jakobsen, A.
Publicado 2018

MicroRNA-126 and epidermal growth factor-like domain 7–an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial

por Hansen, T F, Christensen, R dP, Andersen, R F, Sørensen, F B, Johnsson, A, Jakobsen, A
Publicado 2013